Testing the possible inhibition of proteasome by direct interaction with ubiquitylated and aggregated huntingtin

Brain Research Bulletin

Volumn 72, Issue 2-3 SPEC. ISS., 2007, Pages 121-123

  Valera, Adriana G ^a   Díaz Hernández, Miguel ^a   Hernández, Félix ^a   Lucas, José J ^a  

^a CENTRO DE BIOLOGÍA MOLECULAR SEVERO OCHOA   (Spain)

Author keywords

Filaments; Huntington's disease; Inclusion bodies; Proteasome activity

Indexed keywords

HUNTINGTIN; PROTEASOME;

ARTICLE; ENZYME ACTIVITY; ENZYME INHIBITION; EUKARYOTE; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN INTERACTION; UBIQUITINATION;

ANIMALS; HUMANS; HUNTINGTON DISEASE; INCLUSION BODIES; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; PROTEASOME ENDOPEPTIDASE COMPLEX; UBIQUITIN;

EID: 33847638155     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2006.10.030     Document Type: Article

References (31)

1. Arrasate M., Mitra S., Schweitzer E.S., Segal M.R., and Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431 (2004) 805-810
2. Bence N.F., Sampat R.M., and Kopito R.R. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292 (2001) 1552-1555
3. Bennett E.J., Bence N.F., Jayakumar R., and Kopito R.R. Global impairment of the ubiquitin-proteasome system by nuclear or cytoplasmic protein aggregates precedes inclusion body formation. Mol. Cell. 17 (2005) 351-365
4. Bett J.S., Goellner G.M., Woodman B., Pratt G., Rechsteiner M., and Bates G.P. Proteasome impairment does not contribute to pathogenesis in R6/2 Huntington's disease mice: exclusion of proteasome activator REGγ as a therapeutic target. Hum. Mol. Genet. 15 (2005) 33-44
5. Bowman A.B., Yoo S.Y., Dantuma N.P., and Zoghbi H.Y. Neuronal dysfunction in a polyglutamine disease model occurs in the absence of ubiquitin-proteasome system impairment and inversely correlates with the degree of nuclear inclusion formation. Hum. Mol. Genet. 14 (2005) 679-691
6. Cattaneo E., Zuccato C., and Tartari M. Normal huntingtin function: an alternative approach to Huntington's disease. Nat. Rev. Neurosci. 6 (2005) 9119-9130
7. DeMartino G.N., and Slaughter C.A. The proteasome, a novel protease regulated by multiple mechanisms. J. Biol. Chem. 274 (1999) 22123-22126
8. Díaz-Hernández M., Hernández F., Martin-Aparicio E., Gomez-Ramos P., Moran M.A., Castano J.G., Ferrer I., Avila J., and Lucas J.J. Neuronal induction of the immunoproteasome in Huntington's disease. J. Neurosci. 23 (2003) 11653-11661
9. Díaz-Hernández M., Moreno-Herrero F., Gomez-Ramos P., Moran M.A., Ferrer I., Baro A.M., Avila J., Hernández F., and Lucas J.J. Biochemical, ultrastructural, and reversibility studies on huntingtin filaments isolated from mouse and human brain. J. Neurosci. 24 (2004) 9361-9371
10. Díaz-Hernández M., Torres-Peraza J., Salvatori-Abarca A., Morán M.A., Gómez-Ramos P., Alberch J., and Lucas J.J. Full motor recovery despite striatal neuron loss and formation of irreversible amyloid-like inclusions in a conditional mouse model of Huntington's disease. J. Neurosci. 25 (2005) 9773-9781
11. DiFiglia M., Sapp E., Chase K.O., Davies S.W., Bates G.P., Vonsattel J.P., and Aronin N. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277 (1997) 1990-1993
12. Fink A.L. Protein aggregation: folding aggregates, inclusion bodies and amyloid. Fold Des. 3 (1998) R9-R23
13. Heinsen H., Strik M., Bauer M., Luther K., Ulmar G., Gangnus D., Jungkunz G., Eisenmenger W., and Gotz M. Cortical and striatal neurone number in Huntington's disease. Acta Neuropathol. (Berl.) 88 (1994) 320-333
14. Hernandez F., Diaz-Hernandez M., Avila J., and Lucas J.J. Testing the ubiquitin-proteasome hypothesis of neurodegeneration in vivo. Trends Neurosci. 27 (2004) 66-69
15. Hershko A., and Ciechanover A. The ubiquitin system. Annu. Rev. Biochem. 7 (1998) 425-479
16. Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72 (1993) 971-983
17. Jana N.R., Zemskov E.A., Wang G., and Nukina N. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. Hum. Mol. Genet. 10 (2001) 1049-1059
18. Kopito R.R. Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol. 10 (2000) 524-530
19. Martin-Aparicio E., Yamamoto A., Hernández F., Hen R., Avila J., and Lucas J.J. Proteasomal-dependent aggregate reversal and absence of cell death in a conditional mouse model of Huntington's disease. J. Neurosci. 21 (2001) 8772-8781
20. Nakamura K., Jeong S.Y., Uchihara T., Anno M., Nagashima K., Nagashima T., Ikeda S., Tsuji S., and Kanazawa I. SCA17, a novel autosomal dominant cerebellar ataxia caused by an expanded polyglutamine in TATA-binding protein. Hum. Mol. Genet. 10 (2001) 1441-1448
21. Poirier M.A., Li H., Macosko J., Cai S., Amzel M., and Ross C.A. Huntingtin spheroids and protofibrils as precursors in polyglutamine fibrilization. J. Biol. Chem. 277 (2002) 41032-41037
22. Quinn N., and Schrag A. Huntington's disease and other choreas. J. Neurol. 245 (1998) 709-716
23. Ross C.A. Intranuclear neuronal inclusions: a common pathogenic mechanism for glutamine-repeat neurodegenerative diseases?. Neuron 19 (1997) 1147-1150
24. Ross C.A., and Poirier M.A. What is the role of protein aggregation in neurodegeneration?. Nat. Rev. Mol. Cell Biol. 6 (2005) 891-898
25. Seo H., Sonntag K.C., and Isacson O. Generalized brain and skin proteasome inhibition in Huntington's disease. Ann. Neurol. 56 (2004) 319-328
26. Valera A.G., Diaz-Hernandez M., Hernandez F., Ortega Z., and Lucas J.J. The ubiquitin-proteasome system in Huntington's disease. Neuroscientist 11 (2005) 583-594
27. Venkatraman P., Wetzel R., Tanaka M., Nukina N., and Goldberg A.L. Eukaryotic proteasomes cannot digest polyglutamine sequences and release them during degradation of polyglutamine-containing proteins. Mol. Cell. 14 (2004) 95-104
28. Vonsattel J.P., and DiFiglia M. Huntington disease. J. Neuropathol. Exp. Neurol. 57 (1998) 369-384
29. Wyttenbach A., Carmichael J., Swartz J., Furlong R.A., Narain Y., Rankin J., and Rubinsztein D.C. Effects of heat shock, heat shock protein 40 (HDJ-2), and proteasome inhibition on protein aggregation in cellular models of Huntington's disease. Proc. Natl. Acad. Sci. U.S.A. 14 (2000) 2898-2903
30. Yamamoto A., Lucas J.J., and Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 101 (2000) 57-66
31. Zoghbi H.Y., and Orr H.T. Glutamine repeats and neurodegeneration. Annu. Rev. Neurosci. 23 (2000) 217-247